Cannabis Law Report

AUGUST 17, 2021

–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. We believe the totality of the data is encouraging and supports advancing to Phase 3. Data Highlights. TSC is a leading cause of genetic epilepsy, often occurring in the first year of life as either focal seizures or infantile spasms.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. What about other medical cannabis products? What do experts say? September 23, 2019.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Otherside Farms

JANUARY 24, 2019

Federal regulators have approved two clinical studies testing whether a marijuana-based epilepsy drug may help prevent seizures among epileptic children. Source: FDA Approves Marijuana-Based Epilepsy Drug For Use On Kids In Clinical Trials. Although both studies will enroll 25 patients initially, the U.S. In the upcoming U.S.

Clinical Trials 45

Clinical Trials Epilepsy Marijuana Pharmaceutical 45

Cannabis Law Report

JUNE 5, 2019

Press Release: Thailand Government Pharmaceutical Organization. The Pharmaceutical Organization, Department of Medical Affairs, signed a joint research on standard quality medical marijuana extracts for patients with chemo-allergic cancer, epilepsy, muscle contraction in patients with deteriorating nerve sheaths. 30 May 2019.

Pharmaceutical 40

Pharmaceutical Extraction Epilepsy Research and Development 40

Veriheal

FEBRUARY 21, 2023

” Restricting qualifying conditions also results in limited data collection, hindering the collective understanding of medical cannabis. Furthermore, Nugg MD’s data shows just how vital MMJ access has become in modern society’s health landscape. Many patients take MMJ for more reasons than one.

Access 98

Access Patients Chronic Pain Conditions 98

Cannabis Law Report

SEPTEMBER 13, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

Cannabis Law Report

NOVEMBER 16, 2021

Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Recruitment for the Phase 2 trial will begin immediately, and efficacy data is expected by the end of first quarter of 2022. “To MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

OCTOBER 26, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that Chris Chapman, M.D., Chapman has operated Chapman Pharmaceutical Consulting, Inc., About MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

JANUARY 16, 2022

Malaysia’s National Pharmaceutical Regulatory Agency (NPRA) previously approved a prescription medicine derived from cannabis in 2014 to treat muscle spasms and spasticity from multiple sclerosis. Sativex was developed by GW Pharmaceuticals, a maker of cannabinoid therapeutics based in Ireland.

Research and Development 98

Research and Development Pharmaceutical Epilepsy Medicine 98

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. Enquiries: GW Pharmaceuticals plc.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

MMJ Recs

NOVEMBER 17, 2023

The community impact is visible in several key areas: Healthcare Advancements MMJ has expanded the range of treatment options available to patients, offering an alternative to conventional pharmaceuticals. MMJ is known for its efficacy in treating various medical issues, including chronic pain, epilepsy, multiple sclerosis, and more.

Chronic Pain 98

Chronic Pain Therapy Research and Development Treatment 98

Cannabis Law Report

JULY 24, 2019

It will be the first to have meaningful and consistent data of how medicinal cannabis has helped when properly prescribed as part of a full treatment pathway.” Dr Mikael Sodergren , Managing Director and Academic Lead at Sapphire Medical Clinics said: “Medicinal cannabis is a new and exciting field.

Epilepsy 40

Epilepsy Medicine Treatment Patients 40

Freedom Leaf

OCTOBER 15, 2018

On September 28, the DEA designated Epidiolex —a plant-based CBD pharmaceutical manufactured by the UK-based GW Pharmaceuticals—a Schedule V drug in the government’s list of controlled substances. Frontier Data predicts total sales of all CBD products in the U.S. Frontier Data predicts total sales of all CBD products in the U.S.

DEA 51

DEA CBD Pharmaceutical Epilepsy 51

Cannabis Law Report

DECEMBER 1, 2019

A young girl with a drug-resistant form of epilepsy is believed to be the first and only patient in Singapore who has been given approval to use cannabis-derived medication. The move follows approvals by lawmakers in the United States to use the medication to treat rare kinds of childhood epilepsy in that country.

Epilepsy 59

Epilepsy Cannabinoids Therapy Treatment 59

Cannabis Law Report

AUGUST 24, 2019

The report reveals… MGC Pharmaceuticals is set to kick off a controlled trial to discover if its medical cannabis product for the treatment of drug-resistant epilepsy has any impact on driving performance.

Epilepsy 45

Epilepsy Pharmaceutical Data Safety 45

CannaTech

AUGUST 9, 2018

We are delighted to introduce you to some new friends set to make a big impact on the medical cannabis advocacy scene… the creators of a new documentary called Separating the Strains ; a deeply personal narrative that charts the reality of living with epilepsy, with and without cannabis medication as a treatment option.

Strains 69

Strains Epilepsy Advocacy Medicine 69

The Cannigma

JUNE 15, 2021

The first clinical research done on CBD as a potential treatment for epilepsy was in 1980, but the information gleaned didn’t make its way to the public eye until decades later. However, the scientific data on CBG is nowhere near as developed as what we have on CBD. Shutterstock). One of the leading cannabis clinicians in the U.S.,

CBD 122

CBD Research and Development Epilepsy Extraction 122

Kind Meds (Cannabis Education Blog)

NOVEMBER 18, 2020

For example, many anti-anxiety pharmaceuticals are habit-forming, entail significant negative side effects, and can also cause physical problems such as diminished mobility or coordination. Even doses higher than 1,000mg have been safely administered in testing, and CBD is considered safe for children for the treatment of epilepsy.

Treatment 111

Treatment Conditions CBD Clinical Trials 111

Veriheal

MARCH 23, 2023

Japan’s latest Cannabis Control Law revisions would apply to pharmaceutical-grade medicinal cannabis products. The report states that the revision is an essential move for ensuring the legal use of cannabis-derived epilepsy drug Epidiolex , which is currently being reviewed as part of a series of clinical trials in Japan.

Legalization 68

Legalization Marijuana Clinical Trials Seed-To-Sale 68

Cannabis Law Report

APRIL 4, 2019

Further there is a growing body of evidence that various forms of cannabis could help in the treatment of epilepsy and seizures, post-traumatic stress disorder (PTSD), glaucoma, dementia, Alzheimers, autism, fibromyalgia and a range of auto-immune diseases.

Cultivation 40

Cultivation Research and Development Chronic Pain Data 40

Veriheal

DECEMBER 28, 2021

This is according to recent data from a report published by Market Research Future (MRT) – a pioneer in market analysis. For example, pharmaceutical-grade cannabis is being sold across the fast-evolving retail pharmacy landscape. by the year 2027 , at which point the market could be worth a staggering $33.2 Alzheimer’s.

Research and Development 98

Research and Development Chronic Pain Treatment Medicine 98

Cannabis Law Report

FEBRUARY 15, 2019

The Singapore Online Citizen reports… Law & Home Affairs Minister K Shanmugam says that pharmaceutical companies are hiding their intentions behind a smokescreen when it comes to cannabis. These can be administered through pharmaceutical products such as oral solutions and sprays. It‘s bunkum.”.

Medicine 45

Medicine Pharmaceutical Law Cannabinoids 45

Leaf Science

JULY 23, 2019

In the UK, cannabis was legalized for medicinal purposes in 2018 which saw patients of epilepsy and multiple sclerosis able to access pharmaceutical cannabis derivatives such as Sativex and Epidiolex. We shall look into what these benefits may be and what the science do we have that backs this up.

Strains 74

Strains Cannabinoids Epilepsy THC 74

Cannabis Law Report

JANUARY 10, 2022

This high share is attributable to the rising adoption of THCV for various applications such as epilepsy, arthritis, metabolic disorders, neurological disorders, and pain management. For instance, as of June 2021, InMed Pharmaceuticals, Inc., List To Data Sources. Key Topics Covered: Chapter 1 Methodology and Scope.

Cannabinoids 52

Cannabinoids Clinical Trials Research and Development Supply Chain 52

Veriheal

AUGUST 31, 2020

Essay Summary: Nishtha wants to further research into THC treatment for patients suffering from neurodegenerative diseases like Alzheimer’s and epilepsy , both of which cause neuron death. Essay: “Crowdsourcing User Experience Data for a Targeted Medical Cannabis Journey with Cannamunity” . School: University of Maryland.

Research and Development 117

Research and Development Education Agriculture Patients 117

WeedAdvisor

APRIL 8, 2019

The only actual confirmed benefit of CBD is its effect on Lennox Gastaut Syndrome and Dravet Syndrome – two severe types of epilepsy that do not typically respond to conventional treatment. This led to Epidiolex, the first FDA-approved pharmaceutical drug derived from CBD for the sole purpose of treating LGS and Dravet.

Food 40

Food CBD Research and Development Treatment 40

Cannabis Law Report

MAY 7, 2019

is an emerging pharmaceutical and IP development company, who, through its 100% owned subsidiary Cannevert Therapeutics Ltd. (“CTL“), Veritas Pharma Inc. CTL“), is advancing the science behind medical cannabis. CTL’s unique value proposition uses a low-cost research and development model to help drive shareholder value and speed-to-market.

Compliance 63

Compliance Compliance Research and Development Strains 63

Veriheal

JULY 5, 2021

The self-reported data was logged between June 6, 2016, and July 8, 2019. The UNM researchers noted that, since nausea is just one symptom, CBD may be a better option for relieving the symptoms associated with other types of medical conditions, such as epilepsy and chronic pain. Motion sickness.

THC 52

THC CBD Treatment Cannabinoids 52

Veriheal

MAY 31, 2022

According to data released by the Centers for Disease Control and Prevention , there were an estimated 2,620 opioid overdose deaths in Texas between Aug. physicians began over-prescribing opioids like oxycodone due to reassurance from pharmaceutical companies that they were not addictive—which patients quickly discovered to be untrue.

Programs 52

Programs Chronic Pain Treatment Conditions 52

Cannabis Law Report

JUNE 1, 2021

Prior to UroGen, Mr. Barbera held various leadership roles at Dendreon Pharmaceuticals, Allergan, and Medimmune, among others. Barbera served as the Vice President of Market Access at UroGen Pharma and played a critical role in the launch of the company’s first commercial product, Jelmyto ®.

Research and Development 66

Research and Development Treatment Pharmaceutical Patients 66

Cannabis Law Report

DECEMBER 9, 2019

Although official uses (outside of treatment for childhood epilepsy) have not been officially approved by the FDA, early results from research has resulted in consumers flocking to the compound of their own accord and at their own risk. Millions of individuals are reporting CBD having aided in helping them with: Anxiety.

Pets 59

Pets CBD Research and Development Epilepsy 59

CannaTech

OCTOBER 14, 2018

billion by 2022, according to New Frontier Data, a premier cannabis data analytics firm. Food and Drug Administration’s approval of a CBD-based drug that treats patients with rare forms of epilepsy by reducing seizures. In the U.S. One of the best examples is a recent study that led to the U.S.

Hemp 53

Hemp Research and Development Agriculture Seed-To-Sale 53

Project CBD

FEBRUARY 28, 2023

HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. Epilepsy Behav. Consumers spent roughly $31.3 increase in annual sales.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

NOVEMBER 15, 2021

–(BUSINESS WIRE)– #earnings — Virpax ® Pharmaceuticals, Inc. Finally, we recently acquired the worldwide rights to VRP324, which is an intranasal pharmaceutical-grade cannabidiol product candidate for the management of epilepsy in children (rare pediatric disease) and adults. About Virpax Pharmaceuticals.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

MARCH 3, 2020

Courtney Parker, Pensacola Store Manager amplifies this goal: “At MÜV our main priority is to combine pharmaceutical industry precision with an engaging and compassionate patient experience. We strive to make a firsthand connection with every patient or caretaker to provide them with reliable and effective cannabis based therapies.

Dispensary 64

Dispensary Patients Cannabis Wellness and Beauty 64

Cannabis Law Report

JANUARY 20, 2022

Earlier in 2021, Eleusis welcomed four new directors to its Board: David Socks, former CEO of Phathom Pharmaceuticals, joining as Chairman, Robert Hershberg, M.D., former CBO and CSO of Celgene, John Tucker, CEO of SC Pharmaceuticals, and Esther van den Boom, Managing Partner at van den Boom & Associates. __.

Therapy 52

Therapy Research and Development Business Access 52

Cannabis Law Report

DECEMBER 20, 2021

Data To Support Regulatory Filings in the United States. –(BUSINESS WIRE)– #pharma — Virpax ® Pharmaceuticals, Inc. About Virpax Pharmaceuticals. First Patient Expected to be Enrolled by Q2 of 2022. BERWYN, Pa.–(BUSINESS For more information, please visit www.virpaxpharma.com. About Altasciences.

Clinical Trials 52

Clinical Trials Chronic Pain Pharmaceutical Data 52